Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
Rita Humeniuk, Anita Mathias, Huyen Cao, et al.
Clinical and Translational Science (2020) Vol. 13, Iss. 5, pp. 896-906
Open Access | Times Cited: 236

Showing 1-25 of 236 citing articles:

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
Kenneth H. Dinnon, Sarah R. Leist, Alexandra Schäfer, et al.
Nature (2020) Vol. 586, Iss. 7830, pp. 560-566
Open Access | Times Cited: 639
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
Robert M. Cox, Josef D. Wolf, Richard K. Plemper
Nature Microbiology (2020) Vol. 6, Iss. 1, pp. 11-18
Open Access | Times Cited: 392
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
Florence Ader, Maude Bouscambert‐Duchamp, Maya Hites, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 2, pp. 209-221
Open Access | Times Cited: 302
Remdesivir against COVID-19 and Other Viral Diseases
Jakob J Malin, Isabelle Suárez, Vanessa Priesner, et al.
Clinical Microbiology Reviews (2020) Vol. 34, Iss. 1
Open Access | Times Cited: 268
Remdesivir: First Approval
Yvette N. Lamb
Drugs (2020) Vol. 80, Iss. 13, pp. 1355-1363
Open Access | Times Cited: 248
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
Colin Baigent, Stephan Windecker, Daniele Andreini, et al.
European Heart Journal (2021) Vol. 43, Iss. 11, pp. 1059-1103
Open Access | Times Cited: 147
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
Yingjun Li, Liu Cao, Ge Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2785-2793
Closed Access | Times Cited: 129
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
Rita Humeniuk, Anita Mathias, Brian J. Kirby, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 5, pp. 569-583
Open Access | Times Cited: 115
Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
Vanessa Monteil, Matheus Dyczynski, Volker M. Lauschke, et al.
EMBO Molecular Medicine (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 105
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 98
Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
Catherine Z. Chen, Paul Shinn, Zina Itkin, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 88
Cardiac Adverse Events With Remdesivir in COVID-19 Infection
Anupam Gupta, Barbara M Parker, Vikash Priyadarshi, et al.
Cureus (2020)
Open Access | Times Cited: 81
Repurposing drugs for the management of COVID-19
Jacopo Cusinato, Ylenia Cau, Anna Maria Calvani, et al.
Expert Opinion on Therapeutic Patents (2020) Vol. 31, Iss. 4, pp. 295-307
Closed Access | Times Cited: 78
New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
Muneerah M Aleissa, Emily A. Silverman, Luisa M. Paredes Acosta, et al.
Antimicrobial Agents and Chemotherapy (2020) Vol. 65, Iss. 1
Open Access | Times Cited: 72
Disease-drug and drug-drug interaction in COVID-19: Risk and assessment
Devendra Kumar, Neerja Trivedi
Biomedicine & Pharmacotherapy (2021) Vol. 139, pp. 111642-111642
Open Access | Times Cited: 69
ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential
Subrata Deb, Anthony Allen Reeves, Robert Hopefl, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 655-655
Open Access | Times Cited: 64
Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review
Maryam Nabati, Homa Parsaee
Cardiovascular Toxicology (2021) Vol. 22, Iss. 3, pp. 268-272
Open Access | Times Cited: 62
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
Xuanting Wang, Carolina Q. Sacramento, Steffen Jockusch, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 59
Prodrugs of a 1′-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV
Richard L. Mackman, Hon C. Hui, Michel Perron, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 8, pp. 5001-5017
Closed Access | Times Cited: 58
Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
Zhonglei Wang, Liyan Yang, Xian-qing Song
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 48
Remdesivir: A Review in COVID-19
Hannah A. Blair
Drugs (2023) Vol. 83, Iss. 13, pp. 1215-1237
Open Access | Times Cited: 35
Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
Ling Ye, Shicheng Fan, Pengfei Zhao, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 9, pp. 3598-3637
Open Access | Times Cited: 31
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
Ecofriendly bioanalytical validated RP-HPLC method for simultaneous determination of COVID-19 co-prescribed drugs employing quality by design and green chemistry
Sohair mohamed aboelghar, Maha A. Hegazy, Hebatallah A. Wagdy
Microchemical Journal (2024) Vol. 200, pp. 110292-110292
Closed Access | Times Cited: 9
Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID‐19
Marinella Lauriola, Arianna Pani, Giovanbattista Ippoliti, et al.
Clinical and Translational Science (2020) Vol. 13, Iss. 6, pp. 1071-1076
Open Access | Times Cited: 63
Page 1 - Next Page

Scroll to top